Get to Know Dr. Daniel Labow
Dr. Daniel M. Labow, a native of Canada, received his medical degree from Brown University after attending the University of Pennsylvania. He did a surgical residency at University of Chicago and completed a surgical oncology fellowship at Memorial Sloan Kettering in New York. He’s currently the System Chair of Surgical Services for Nuvance Health in Connecticut.
He joined Mount Sinai Medical Center, which includes both the hospital and school of medicine, in 2004. Just a few years later, he started the hyperthermic intraperitoneal chemotherapy program in 2007 at Mount Sinai Medical Center in New York, and has watched the program grow rapidly with success stories that include mesothelioma patients.
“It is not the one silver bullet that everyone wants to find, and it doesn’t apply to everyone,” Labow told Asbestos.com. “But, it certainly has become an important part of treatment for many.”
Labow uses HIPEC with cytoreductive surgery on patients with mesothelioma, colorectal cancer, stomach cancer, cancer of the appendix, ovarian cancer and other cancers confined to the peritoneal cavity.
He spends much of his time working on the diagnosis and treatment of primary and metastatic malignancies, including gastric and esophageal cancer and pancreatic and liver malignancies. He has worked extensively with minimally invasive surgical techniques.
Specialties of Dr. Daniel Labow
- Peritoneal mesothelioma
- Minimally invasive surgery
- Hyperthermic intraperitoneal chemotherapy
Dr. Daniel Labow’s Experience and Medical Education
- Nuvance Health
- Mount Sinai Medical Center
- Dartmouth-Brown Medical Program at Brown University (Medical school)
- University of Chicago (Residency)
- Memorial Sloan Kettering Cancer Center (Fellowship)
Dr. Daniel Labow’s Awards and Certifications
- 2013 Best Doctors, New York magazine
- 2011 Top Doctors — New York Metro Area Award, named by Castle Connolly
- 2007 Robert Paradny Teaching Award
- University of Chicago Hospitals administrative chief resident, 2001
- Memorial Sloan Kettering Cancer Center chief research fellow, 1998
Testimonials for Dr. Daniel Labow
“Nothing in life is a guarantee, but the guarantee for me was that HIPEC was the best treatment,” said Rosanne Mari, a patient from New Jersey who had the procedure in combination with cancer surgery. “I am a better, healthier person, and for that I am forever grateful to Dr. Labow.”
Publications of Dr. Daniel Labow
- Labow, D.M. et al. (2020). Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World Journal of Surgical Oncology.
- Sarpel, U. et al. (2020). The importance of primary tumor origin in gastrointestinal malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Surgical Oncology.
- Sullivan, B.J. et al. (2020). Distal pancreatectomy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Identifying risk and improving patient selection. The American Journal of Surgery.